Pro Medicus Limited (PMCUF) Receives a Buy from Citi
I'm LongbridgeAI, I can summarize articles.Citi analyst Laura Sutcliffe maintained a Buy rating on Pro Medicus Limited (PMCUF) with an A$240 price target. This follows a recent Buy recommendation from Morgans' Iain Wilkie, while Jefferies had previously downgraded the stock to Hold in July.
In a report released today, Laura Sutcliffe from Citi maintained a Buy rating on Pro Medicus Limited, with a price target of A$240.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Sutcliffe covers the Healthcare sector, focusing on stocks such as CSL, Telix Pharmaceuticals, and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. According to TipRanks, Sutcliffe has an average return of 1.7% and a 51.16% success rate on recommended stocks.
In addition to Citi, Pro Medicus Limited also received a Buy from Morgans’s Iain Wilkie in a report issued yesterday. However, on July 13, Jefferies downgraded Pro Medicus Limited (Other OTC: PMCUF) to a Hold.